Abstract
Resistant hypertension is defined as blood pressure that remains uncontrolled in spite of ≥ 3 antihypertensive medications at effective doses, ideally including a diuretic. Although exact prevalence is unknown, clinical trials suggest that 20% to 30% of study participants are resistant. Hyperaldosteronism, obesity, refractory volume expansion, and obstructive sleep apnea are common findings in resistant hypertension patients. Multiple studies indicate that primary aldosteronism (PA) is common (∼ 20%) in patients with resistant hypertension. Screening for PA is recommended for most patients with resistant hypertension, ideally by measurement of 24-hour urinary aldosterone excretion, or by the plasma aldosterone/plasma renin activity ratio. Successful treatment of resistant hypertension is predicated on improvement of lifestyle factors; accurate diagnosis and treatment of secondary causes of hypertension; and use of effective multidrug regimens. A long-acting diuretic, specifically chlorthalidone, is recommended as part of the treatment regimen. Recent studies demonstrate that mineralocorticoid receptor antagonists provide substantial antihypertensive benefit when added to multidrug regimens, even in patients without demonstrable aldosterone excess.
Similar content being viewed by others
References and Recommended Reading
Calhoun DA, Jones D, Textor S, et al.: AHA Scientific Statement. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403–1419.
Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003, 290:199–206.
Ma J, Stafford RS: Screening, treatment, and control of hypertension in US private physician offices, 2003-2004. Hypertension 2008, 51:1275–1281.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.
Ma J, Lee K, Sttaford RS: Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension 2006, 48:846–852.
Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al.: Characterization of resistant hypertension. Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008, 168:1159–1164.
Nieto FJ, Young TB, Lind BK, et al.: Association of sleepdisordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA 2000, 283:1829–1836.
Peppard PE, Young T, Palta M, et al.: Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000, 342:1378–1384.
Logan AG, Perlikowski SM, Mente A, et al.: High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens 2001, 19:2271–2277.
Becker HF, Jerrentrup A, Ploch T, et al.: Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003, 107:68–73.
Robinson GV, Stradling JR, Davies RJO: Obstructive sleep apnea/hypopnoea syndrome and hypertension. Thorax 2004, 59:1089–1094.
Textor SC: Atherosclerotic renal artery stenosis. Overtreated but underrated? J Am Soc Nephrol 2008, 19:656–659.
Conn JW: Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955, 45:3–17.
Rossi GP, Bernini G, Caliumi C, et al.: A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293–2300.
Gordon RD, Ziesak MD, Tunny TJ, et al.: Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993, 20:296–298.
Gordon RD, Stowasser M, Tunny TJ, et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315–318.
Mosso L, Carvajal C, González A, et al.: Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161–165.
Calhoun DA, Nishizaka MK, Zaman MA, et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892–896.
Calhoun DA: Is there an unrecognized epidemic of primary aldosteronism? Pro. Hypertension 2007, 50:447–453.
Gallay BJ, Ahmad S, Xu L, et al.: Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:669–705.
Eide IK, Torjesen PA, Drolsum A, et al.: Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217–2226.
Strauch B, Zelinka T, Hampf M, et al.: Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003, 17:349–352.
Douma S, Petidis K, Doumas M, et al.: Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008, 371:1921–1926.
Rocha R, Rudolph AE, Frierdich GE, et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802–H1810.
Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893–901.
Brown NJ: Aldosterone and vascular inflammation. Hypertension 2008, 51:161–167.
Rossi GP, Sacchetto A, Visentin P, et al.: Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996, 27:1039–1045.
Fox CS, Larson MG, Hwang S-J, et al.: Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int 2006, 69:2064–2069.
Nishizaka MK, Zaman MA, Green SA, et al.: Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004, 109:2857–2861.
Holaj R, Zelinka T, Wichterle D, et al.: Increased intimamedia thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007, 25:1451–1457.
Milliez P, Girerd X, Plouin PF, et al.: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243–1248.
Pimenta E, Gaddam KK, Pratt-Ubunama MN, et al.: Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens 2007, 25:2131–2137.
Pimenta E, Gaddam KK, Pratt-Ubunama MN, et al.: Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension 2008, 51:339–344.
Tonelli M, Jose P, Curhan G, et al.: Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomized trial. BMJ 2006, 332:1426–1431.
Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of lowdose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925–930.
Calhoun DA: Management of hyperaldosteronism and hypercortisolism. In Hypertension Primer: The Essentials of High Blood Pressure: Basic Science, Population Science, and Clinical Management. Edited by Izzo JL, Sica D, Black HR. Philadelphia: Lippincott Williams & Wilkins; 2008:564–567.
Pizzolo F, Pavan C, Corrocher R, et al.: Laboratory diagnosis of primary aldosteronism, and drospirenone-ethinylestradiol therapy. Am J Hypertens 2007, 20:1334–1337.
Mattsson C, Young WF Jr: Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006, 2:198–208.
Young WF Jr, Klee GC: Primary aldosteronism: diagnostic evaluation. Endocrinol Metab Clin North Am 1988, 17:367–395.
Rossi GP, Belfiore A, Bernini G, et al.: Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007, 50:424–431.
Nwariaku FE, Miller BS, Auchus R, et al.: Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg 2006, 141:497–503.
Sawka AM, Young WF, Thompson GB, et al.: Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001, 135:258–261.
Rossi GP, Bolognesi M, Rizzoni D, et al.: Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008, 51:1366–1371.
Catena C, Colussi G, Lapenna R, et al.: Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007, 50:911–918.
Taler SJ, Textor SC, Augustine JE: Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002, 39:982–988.
Ernst ME, Carter BL, Goerdt CJ, et al.: Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:352–358.
Ouzan J, Perault C, Lincoff AM, et al.: The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333–339.
Lane DA, Shah S, Beevers DG: Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007, 25:891–894.
Chapman N, Dobson J, Wilson S, et al.: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839–845.
Flack JM, Oparil S, Pratt JH, et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41:1148–1155.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gonzaga, C.C., Calhoun, D.A. Resistant hypertension and hyperaldosteronism. Current Science Inc 10, 496–503 (2008). https://doi.org/10.1007/s11906-008-0092-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-008-0092-0